Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI +0.88%66 EV-to-EBIT is 19.22 as of Aug. 17, 2026, which is 105% above its 10-year median of 9.39. GuruFocus rates NSE:BALAXI with a GF Score™ of 66/100 and a GF Value™ of ₹68.89 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 683 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 56.37% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Balaxi Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was ₹1,304 Mil.
Balaxi Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's EV-to-EBIT falls into.
Balaxi Pharmaceuticals's current Enterprise Value is ₹1,767 Mil.
Balaxi Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balaxi Pharmaceuticals (NSE:BALAXI) has a EV-to-EBIT of 19.22 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Balaxi Pharmaceuticals and its competitors. This is 105% above median its historical median of 9.39. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #385 out of 683 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Balaxi Pharmaceuticals' EV-to-EBIT too high?
Balaxi Pharmaceuticals' current EV-to-EBIT of 19.22 is 105% above median its 10-year median of 9.39. The Drug Manufacturers industry median EV-to-EBIT is 15.94. Balaxi Pharmaceuticals' value of 19.22 is 20.6% above this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #385 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #385 out of 683 companies for EV-to-EBIT. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.94. Balaxi Pharmaceuticals' value of 19.22 is 20.6% above this benchmark. While the company's 10-year median is 9.39 vs. the industry median of 15.94, Balaxi Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.94, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current EV-to-EBIT of 19.22 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current EV-to-EBIT is 19.22, which is 105% above median its own 10-year median of 9.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹68.89, compared to a current price of ₹24.21 — trading 64.9% below its estimated fair value. The current EV-to-EBIT is 19.22, which is 105% above median its 10-year median of 9.39 and 20.6% above the Drug Manufacturers industry median of 15.94. Balaxi Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current EV-to-EBIT is 19.22 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.21 is trading 64.9% below its estimated GF Value™ of ₹68.89.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
EV-to-EBIT: 19.22 (105% above median its 10-year median of 9.39)
GF Value™: ₹68.89 vs. price of ₹24.21 (64.9% below fair value)
Industry Position: 20.6% above the Drug Manufacturers median (#385 of 683)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
66GF Score
Get the complete analysis for NSE:BALAXI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
